Sikorski quits as troubled Cantab seeks buyer
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Jurek Sikorski resigned as chief executive of Cantab Pharmaceuticals yesterday as the troubled biotech group put itself up for sale.
Jurek Sikorski resigned as chief executive of Cantab Pharmaceuticals yesterday as the troubled biotech group put itself up for sale.
The departure of Mr Sikorski, a former professional footballer, comes eight days after Cantab said its lead drug, a genital warts treatment, had failed in clinical trials. The news wiped 67 per cent off Cantab's share price. The shares yesterday firmed 3p to 82p.
Jeremy Curnock Cook, the biotech entrepreneur and life sciences fund manager, has become executive deputy chairman. Nick Hart, chief operating officer, is to be acting chief executive. Cantab investors have voiced discontent with the management since merger talks with Peptide Therapeutics, a rival vaccines group, broke down.
Credit Suisse First Boston, the investment bank, is conducting a strategic review of the Cantab, which will run out of cash in 2002, two years before it is forecast to make a profit. Analysts said the most likely buyers were the US biotech firms Corixa and Avant. Peptide is not thought to be interested, although industry observers said it made sense for a UK biotech to reverse into Cantab.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments